Parabilis Medicines (PBLS) vs Arcus Biosciences (RCUS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Parabilis Medicines is the larger company by market cap ($3.45 billion vs $2.92 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBLS | RCUS |
|---|---|---|
| Share price | $27.96 | $23.22 |
| Market cap | $3.45B | $2.92B |
| 1-day change | -2.98% | -5.30% |
| YTD return | — | +2.90% |
| 1-year return | — | +74.77% |
| 5-year return | — | -28.70% |
| EPS (TTM) | $-9.51 | $-3.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $247.00M |
| Revenue growth (YoY) | — | -4.26% |
| Net income (latest FY) | — | $-353.00M |
| Operating margin | — | -156.28% |
| Net margin | — | -142.91% |
| 52-week high | $42.49 | $31.74 |
| 52-week low | $24.51 | $14.26 |
| Distance from 52-week high | -34.20% | -26.83% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +49.32% | +71.88% |
| Average volume | 675.43K | 1.32M |
| Shares outstanding | 121.95M | 125.77M |
| Employees | 145 | 601 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
PBLS vs RCUS FAQ
Which is bigger, Parabilis Medicines or Arcus Biosciences?
Parabilis Medicines (PBLS) is larger, with a market capitalization of $3.45B compared with $2.92B for Arcus Biosciences (RCUS).
Are Parabilis Medicines and Arcus Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.